ArticleJournal of nanobiotechnology2025
Kupffer cells biomimetic nanoparticles alleviate sepsis related liver injury.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomimetic Targeted Drug Delivery for Liver Failure in Abdominal Sepsis: Focus on Autologous Erythrocyte Ghosts.International journal of molecular sciences · 2026Review
- Targeting Kupffer Cell CD44-Mediated Ammonia Death via the ELAVL1-GLS Metabolic Circuit in Radiation-Induced Liver Disease.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The mechanism of sepsis related liver injury (SRLI) is unclear and its treatment method is unsatisfactory. The aim of this study was to investigate the effects of BRCC3 on SRIL and preparation of kupffer cells membrane encapsulated ZIF-8 loaded BRCC3 siRNA (K-EVs@ZIF-8@siRNA) to target BRCC3 to treatment of SRLI. Liver tissues from control mice and SRLI mice were used for RNA sequencing for searching differential genes. The cercal ligation and punchure (CLP) model and lipopolysaccharide (LPS) model were used to evaluate the mechanisms of BRCC3 and the effects of K-EVs@ZIF-8@siRNA on SRLI. The results of RNA-Seq showed BRCC3 and NLRP1were significantly increased in Kuepfer cells of liver tissues of SRLI mice. BRCC3 and NLRP1 have co-localization in Kuepfer cells. It was also found that knock out BRCC3 had protective effects on SRLI via deubiquitylation modification of NLRP1 to inhibit of NLRP1. K-EVs@ZIF-8@siRNA was successfully prepared in this study and exhibited the characteristics of nanoparticles. K-EVs@ZIF-8@siRNA could be enriched in liver tissues and also be absorbed by Kuepfer cells. K-EVs@ZIF-8@siRNA significantly alleviated SRLI by inhibition the BRCC3/NLRP1 signaling pathway. In conclusion, BRCC3 as a key marker was identified in SRLI and K-EVs@ZIF-8@siRNA was successfully prepared for treating SRLI. This study provides a new target and treatment for SRLI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.